|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||7.09 - 7.09|
|52-week range||6.39 - 9.25|
|Beta (5Y monthly)||1.07|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
LONDON, January 26, 2022--Silence Therapeutics Announces SLN360 Phase 1 Data Accepted for Late-Breaking Presentation at ACC Meeting in April 2022.
LONDON, January 18, 2022--Dr. Marie Wikström Lindholm, SVP, Molecular Design at Silence Therapeutics, elected to Board of Directors of Oligonucleotide Therapeutics Society.
Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect Virtual Conference 5 January 2022 LONDON, Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that the Company will participate in a fireside chat during the H.C. Wainwright BioConnect Virtual Conferen